Finland's Oriola Q1 net sales fall 2.2%

Oriola Oyj

29/04/2026 06:38

Overview

Finland pharmaceutical distributor's Q1 invoicing up 8.1% yr/yr, net sales fell 2.2%

Adjusted EBITDA for Q1 rose 2% yr/yr, net loss narrowed to EUR -2.0 mln

Company expects 2026 adjusted EBITDA to increase from prior year

Outlook

Oriola expects 2026 adjusted EBITDA to increase from 2025 (EUR 35.1 mln)

Result Drivers

PHARMACEUTICAL DISTRIBUTION VOLUMES - Co said growth in net sales was driven by higher volumes in pharmaceutical distribution in Finland and Sweden, and high volumes in parallel imports in Sweden

FINNISH WHOLESALE AND DOSE DISPENSING - Co said improvement in Products segment was driven by growth in Finnish wholesale and dose dispensing businesses

WEAK ADVISORY SERVICES - Co said advisory services had a slow start to the year, resulting in a decline in net sales and lower adjusted EBITDA in the Services segment

Company press release: ID:nWkr7nvN3m

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 EPS
-EUR 0.01


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Oriola Oyj is €1.00, about 5.8% above its April 28 closing price of €0.95

The stock recently traded at 10 times the next 12-month earnings vs. a P/E of 11 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)